Results 221 to 230 of about 1,110,252 (341)

CRISPR‐Cas9‐Loaded Theranostic Liposomes for Enhancing Radiosensitization of Prostate Cancer through POLD4 Gene Editing under Real‐Time MRI Monitoring

Advanced Science, EarlyView.
This study identifies POLD4 as a potential prostate cancer radiosensitization target through transcriptome sequencing. By encapsulating POLD4‐targeted CRISPR/Cas9 plasmids and USPIONs in cationic liposomes, an MRI‐monitored gene‐editing platform is established.
Xuhui Fan, Ruru Zhang, Linjun Yang, Shixiong Chen, Meijuan He, Yongqiang Wang, Linjie Huang, Jianfeng Zeng, Shuwang Wu, Mingyuan Gao, Han Wang   +10 more
wiley   +1 more source

A case of transformation of Waldenström's Macroglobulinemia to diffuse large B cell lymphoma. [PDF]

Oxf Med Case Reports
Ali MB, Kline K.
europepmc   +1 more source

Anionic Liposomes as Optimal Membrane Fusion Carriers Enabling in Situ Multiplexed Detection of Extracellular Vesicle MicroRNAs

Advanced Science, EarlyView.
A novel strategy for in situ multiplexed miRNA analysis of plasma extracellular vesicles (EValarm) has been developed. EValarm enables straightforward detection of different extracellular vesicle miRNAs from plasma samples through systematic screening of liposome surface charges, without requiring complex pretreatment steps, and achieves satisfactory ...
Jing‐Yuan Ma, Xiao Wang, Yuhan Cai, Guancheng Wang, Mingze Lu, Kaizheng Feng, Ying Zhao, Xue Wu, Xiaoping Zhang, Haoan Wu, Wei Yu, Ming Ma, Zheng Ge, Yu Zhang   +13 more
wiley   +1 more source

Global, regional, and national patterns of change in the burden of Hodgkin lymphoma from 1990 to 2021: an analysis of the global burden of disease study 2021 and projections to 2035. [PDF]

Ann Hematol
Pu H, Zhang J, Song Y.
europepmc   +1 more source

Cell‐Free DNA‐Based Theranostics for Inflammatory Disorders

Advanced Science, EarlyView.
Summary on the dual potential of cfDNA as biomarkers and therapeutic targets for inflammatory disorders. Figure was created with BioRender.com. ABSTRACT Inflammatory disorders are characterized by immune‐mediated inflammatory cascades that can affect multiple organs.
Jiatong Li, Yumei Wang, Xiaoxi Fan, Miao Xu, Jiawen Li, Wenfei Tan, Jianxiang Zhang, Heran Li   +7 more
wiley   +1 more source

Practical implications of the World Health Organization Reporting System for Lymph Node, Spleen, and Thymus Cytopathology: Categories and ancillary testing for subtyping of hematolymphoid tumors on FNA biopsy cytopathology using a pattern-based approach. [PDF]

Cancer Cytopathol
Ehinger M, Calaminici M, Cozzolino I, Zeppa P, Field AS.   +4 more
europepmc   +1 more source

HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice [PDF]

, 2017
Esser, Alison K, et al,, Harding, John C, Ratner, Lee, Rauch, Daniel A, Ross, Michael H, Su, Xinming, Vij, Kiran, Weilbaecher, Katherine N, Wu, Kevin, Xiang, Jingyu, Xu, Yalin   +11 more
core   +2 more sources

Targeting DAP5 Disrupts Alternate Mode of Translational Initiation in Tregs and Potentiates Antitumor Immunity

Advanced Science, EarlyView.
Regulatory T cells (Tregs) suppress antitumor immunity. This study identifies that the translation scaffold DAP5/eIF4G2 is upregulated in tumor‐infiltrating Tregs (ti‐Tregs). DAP5 mediates an alternate translation mode to sustain CD25 and MCL‐1 expression, which is critical for ti‐Treg stability and survival in the tumor microenvironment.
Xiaojiang Lai, Guihong Pan, Xixi Feng, Jun Zhang, Yunxia Li, Shanmeizi Zhao, Zhenming Lin, Yun Feng, Wei Bao, Hongyan Yang, Chengmei Xie, Chen Huang, Jun Wang   +12 more
wiley   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Phase I Study of Mogamulizumab in Combination with Pembrolizumab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma-A National Cancer Institute Experimental Therapeutics Clinical Trials Network (NCI-ETCTN) Trial. [PDF]

Cancers (Basel)
Joffe E, Kumar A, Tuscano JM, Moskowitz AJ, Owens C, Noy A, Palomba ML, Zelenetz AD, Ni A, Sharon E, Vardhana S.   +10 more
europepmc   +1 more source